Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.67 |
| ▸ | PAM | P19021 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL1190981 | 1.00 | DGKA (0.67) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methylene Chloride SCHEMBL3349968 | 0.98 | DGKA (0.64) | DGKAPAMTSHRMAPTCYP1A2 | |
| Methylene Chloride SCHEMBL6898274 | 0.98 | DGKA (0.64) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL8375548 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL3151787 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL116995 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL454 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| Hexane SCHEMBL2349171 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL6443707 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 | |
| SCHEMBL1645398 | 0.94 | DGKA (0.75) | DGKAPAMTSHRMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199595-A1 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240059684-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20240059683-A1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11834444-B2 | Processes for preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3383372-B1 | SOLID DISPERSIONS COMPRISING A SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116942616-A | Solid dispersion comprising sGC stimulators | 赛克里翁治疗有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3481820-B1 | SOLID FORMS OF AN SGC STIMULATOR | CYCLERION THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11773089-B2 | Process for preparation of soluble guanylate cyclase stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4249488-A2 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3481818-B1 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | CYCLERION THERAPEUTICS INC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-6255326-B1 | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASES | AVENTIS PHARMA LIMITED (GB) | 2001-07-03 | — | — | US | disclosed |
| US-6096768-A | ADMINISTERING A 3, 5, 6-SUBSTITUTED PHENYL COMPOUND FOR THE TREATMENT OF INFLAMMATION AND AUTOIMMUNE DISORDERS | RHONE-POULENC RORER LIMITED (GB) | 2000-08-01 | — | — | US | disclosed |
| US-5935978-A | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group | RHONE-POULENC RORER LIMITED (GB) | 1999-08-10 | — | — | US | disclosed |
| US-5840724-A | COMPOUNDS FOR TUMOR NECROSIS FACTOR OR ENZYME INHIBITORS OF PHOSPHODIESTERASES | RHONE-POULENC RORER LIMITED (GB) | 1998-11-24 | — | — | US | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199595-A1 | NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1B1, GUCY1B2, GUCY1A2 | DGKA 431/4885PAM 557/4885TSHR 1712/4885 |
| US-20240059683-A1 | SOLID FORMS OF AN SGC STIMULATOR | GUCY1A2, PRKG1, GUCY1A1 | DGKA 1332/4885PAM 658/4885TSHR 1197/4885 |
| US-11773089-B2 | Process for preparation of soluble guanylate cyclase stimulators | GUCY1A2, GUCY1B1, GUCY1B2 | DGKA 468/4885PAM 606/4885TSHR 1639/4885 |
| US-20240059684-A1 | NOVEL PROCESS FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B1, GUCY1B2 | DGKA 527/4885PAM 697/4885TSHR 1697/4885 |
| US-11834444-B2 | Processes for preparation of soluble guanylate cyclase stimulators | GUCY1B1, GUCY1B2, GUCY1A2 | DGKA 456/4885PAM 523/4885TSHR 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.